EAN 2022 | sNfL as a prognostic biomarker of MS at an individual level

Jens Kuhle, MD, PhD, University Hospital Basel, Basel, Switzerland, discusses the potential of serum neurofilament light (NfL) for prognostication at an individual level rather than a group level. Evidence shows that NfL levels are lower in younger multiple sclerosis (MS) patients when compared to older patients. Reference ranges for NfL levels that account for the age-dependent increase of blood NfL increase the power of this biomarker on an individual level. Therefore, in context with clinical and MRI findings, NfL could be a useful prognostic marker on an individual level. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.